Hormonal
Older adults (≥65 years) experience adverse events from Tirzepatide significantly earlier (median 12 days) than younger adults (median 31 days), suggesting heightened sensitivity or earlier symptom reporting in this demographic.
If you are over 65 and start Tirzepatide, be extra vigilant in the first two weeks. Side effects like nausea or dizziness may hit you much sooner than they would for a younger person. Report any severe symptoms to your doctor immediately, as discontinuation rates are higher in this age group.
The median time to onset in the ≥65 years age group was significantly shorter than in the <65 years group (12 vs 31 days, P < 0.001).
Why this rating
Based on FAERS data which has high missingness for onset time (only 5% of reports), limiting statistical robustness.
Source
Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
Zhenpo Zhang et al. · Endocrine Connections · 2025
DOI 10.1530/ec-25-0205
More from this paper
- Tirzepatide administration is associated with a high frequency of gastrointestinal adverse events (nausea, diarrhea, vomiting) and injection-site reactions, with a median time to onset of 26 days, occurring predominantly during the dose-escalation phase.Moderate
- Tirzepatide use is associated with novel safety signals including belching, upper respiratory tract infections, and postmenopausal hemorrhage, which are not prominently featured in standard prescribing information.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →